NCI study uses Bellicum's CAR T cell safety switch; Innocutis licenses Sitavig from BioAlliance; Portola initiates andexanet alfa Phase III; Alcobra enrolls first Phase III patient; Cardium becomes Taxus Cardium; Sangamo prices $100m offering; Alexza…
written on 24.03.2014
BioNotebook: First trial for Bellicum's CAR T cell safety switch; deals, trials, financings